Authors: Nemoto, K Shibamoto, Y Ohmagari, J Baba, Y Ebe, K Ariga, H Takai, Y Ouchi, A Sasai, K Shinozaki, M Tsujitani, M Sakaguchi, M Yamada, S Sakamoto, K

Citation: K. Nemoto et al., Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy, ANTI-CANC D, 12(1), 2001, pp. 1-6

Authors: Tsujitani, M Koshimizu, T

Citation: M. Tsujitani et T. Koshimizu, Neural discriminant analysis, IEEE NEURAL, 11(6), 2000, pp. 1394-1401

Authors: Matsuoka, H Shibamoto, Y Kubota, T Tsujitani, M Majima, T

Citation: H. Matsuoka et al., In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas, ONCOL REP, 7(1), 2000, pp. 23-26

Authors: Shibamoto, Y Kubota, T Kishii, K Tsujitani, M

Citation: Y. Shibamoto et al., Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole, RADIOTH ONC, 56(2), 2000, pp. 265-270